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ith Tranilast and its Outcomes (PRESTO) Trial
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illiam F. Penny, MD, Donald E. Cutlip, MD,‡ David R. Holmes, JR, MD*
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OBJECTIVES This study assessed the geographical differences in target vessel revascularization (TVR) after
percutaneous coronary intervention (PCI) in the Prevention of Restenosis With Tranilast and
its Outcomes (PRESTO) trial.
BACKGROUND An aggressive approach to PCI is more common in the U.S. than in other countries. The
impact of this approach on restenosis outcomes has not been studied.
METHODS Using the PRESTO trial, we compared nine-month ischemic TVR after PCI in U.S.-treated
patients (n  5,026) with rates in other countries (n  6,458). We defined TVR as repeat
intervention for chest pain/positive stress test. Additionally, angiographic restenosis (50%
narrowing or 50% loss of gain at nine-month follow-up) was compared between U.S. and
non-U.S. patients within the prespecified angiographic subset (n  2,823). Regression
models were developed to adjust for clinical and lesion-related characteristics.
RESULTS Higher rates of TVR (18% vs. 11%), and angiographic restenosis (65% vs. 48%) were
observed in patients treated in the U.S. as compared with the other patients (p  0.01 for
both comparisons). Patients treated in the U.S. were more likely to be female, diabetic, not
currently smoking, to have unstable angina, and to have a prior PCI. In U.S. patients, lesions
tended to be longer, but less likely to be American College of Cardiology/American Heart
Association class C. After adjusting for clinical and angiographic variables, PCI in the U.S.
was still associated with increased angiographic restenosis and ischemic TVR.
CONCLUSIONS Angiographic restenosis and ischemia-driven TVR rates were higher in patients treated in the
U.S. The difference could only partially be explained by the higher prevalence of measured
adverse clinical and angiographic features. (J Am Coll Cardiol 2006;47:34–9) © 2006 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.07.066the American College of Cardiology Foundation
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ghere are global differences in the revascularization strate-
ies in the management of patients presenting with stable or
nstable angina. Not only are invasive procedures, such as
ardiac catheterization, percutaneous coronary interventions
PCIs), and coronary bypass graft surgery used more com-
only in the U.S. than in other countries, but the timing of
uch interventions differs, with PCI performed earlier dur-
ng the course of an acute coronary syndrome in patients
reated in the U.S. (1–5). A more aggressive revasculariza-
ion approach in most recent trials in patients with acute
oronary syndromes is known to reduce major adverse
ardiovascular outcome, but its effect on restenosis and
arget vessel revascularization (TVR) is largely undefined
6,7). An earlier analysis from the Platelet glycoprotein
Ib/IIIa in Unstable angina: Receptor Suppression Using
ntegrilin Therapy (PURSUIT) trial suggested higher re-
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ouston, Texas; and the University of California/VA Medical Center, San Diego,
alifornia. Richard Edward Kuntz, MD, acted as guest editor for this paper.w
Manuscript received November 29, 2004; revised manuscript received May 27,
005, accepted July 11, 2005.ascularization rates with earlier performance of angioplasty
n a setting of acute coronary syndrome (5). However, the
URSUIT trial antedates current angioplasty results.
The Prevention of Restenosis With Tranilast and its
utcomes (PRESTO) trial was designed to evaluate the
ffects of tranilast, an oral anti-inflammatory agent, on
ajor adverse cardiovascular events and angiographic and
ntravascular (i.e., intravascular ultrasound) end points (8).
his trial not only provided important information on
atients treated in the U.S. but also enrolled patients in
on-U.S. sites, providing an ideal substrate for comparison
f the angiographic restenosis and ischemia-driven TVR
ates among patients treated in the U.S. and other countries.
ith this background, we sought to determine differences
n these outcomes between patients treated at U.S. and
on-U.S. sites.
ETHODS
he PRESTO trial has been described previously (8). In
rief, it was a double blind, placebo-controlled, parallel
roup study of patients after PCI. The primary end point
as the first occurrence of major adverse cardiovascular
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January 3, 2006:34–9 Geographical Differences in Repeat Revascularizationvents within nine months, defined as death, myocardial
nfarction (MI), and/or ischemia-driven TVR. No differ-
nces in outcomes were found in patients treated with the
tudy drug versus placebo. Furthermore, the PRESTO trial
ncluded an angiographic substudy in which enrollees were
equired to undergo follow-up angiography at nine months
or sooner if clinically warranted). Restenosis was defined as
50% stenosis in the treated segment at follow-up, or at
east 50% loss of the original gain in the minimal luminal
iameter. Ischemia-driven TVR was defined as intervention
or chest pain or a positive test for ischemia (exercise stress
est, stress echocardiogram, 24-h Holter monitor, resting
lectrocardiogram evidence of ST-segment depression or
levation in 1 lead, or radionuclide study showing revers-
ble defect). Target vessel failure (TVF) was defined as a
omposite of death, MI, or ischemia-driven TVR. The type
f intervention performed was at the investigator’s discre-
ion, with the exclusion of intracoronary radiation. All
atients gave informed consent to take part in the trial. The
nstitutional review board of each hospital approved the
tudy protocol.
tatistical analysis. The primary clinical outcome in this
tudy was ischemia-driven TVR within nine months after
CI, and the primary angiographic outcome was restenosis
t nine-month follow-up as defined previously. The rates of
VR are reported across geographic location, non-U.S.
ersus U.S. A logistic regression model was developed to
stimate the association between geographic location and
VR. An odds ratio and corresponding 95% confidence
nterval are reported comparing U.S. with non–U.S-treated
atients. An adjusted odds ratio and 95% confidence inter-
al for U.S. versus non-U.S. patients was estimated after
ncluding variables in the logistic regression model that have
nown or assumed association with TVR. These variables
reviously were identified by our group as lesion length, vessel
ize, American College of Cardiology/American Heart Asso-
iation (ACC/AHA) lesion type, previous PCI, diabetes,
moking status, current unstable angina, and gender (9).
essel size was not available in the clinical data; therefore, it
as not included in any of the models. Similar strategies
ere used for analyzing death, MI, TVF, and angiographic
estenosis. Angiographic restenosis was classified on a per-
erson basis as any lesion with restenosis versus none. The
umber of lesions per person was included in the models for
ngiographic restenosis.
Baseline clinical and lesion characteristics are reported sep-
Abbreviations and Acronyms
ACC/AHA  American College of Cardiology/
American Heart Association
MI  myocardial infarction
PCI  percutaneous coronary intervention
TVF  target vessel failure
TVR  target vessel revascularizationrately for U.S. and non-U.S. sites. Continuous variables are meported as mean  one standard deviation, with differences
etween groups tested using t tests; categorical variables are
eported as counts and percentages, with differences be-
ween groups tested using chi-square tests. Nonparametric
ests were incorporated as necessary.
ESULTS
our hundred thirty-two centers (224 in the U.S., 166 in
estern Europe, 27 in Canada, 7 in Eastern Europe, and 8
n Australia/South Africa) enrolled 11,484 patients between
pril 1999 and July 2000. Among these patients, 5,026
44%) were treated in the U.S. and 6,458 (56%) in other
ountries. The angiographic substudy of the PRESTO trial
riginally enrolled 2,823 patients, with 2,096 (74%) provid-
ng angiographic data at nine-month follow-up. A signifi-
antly larger percentage of U.S. patients did not provide
ngiographic follow-up at nine months (31% vs. 22%, p 
.01).
There were several significant differences in baseline
haracteristics between patients treated in the U.S. and
hose treated elsewhere (Table 1). Patients treated in the
.S. were more likely to be female, diabetic, not currently
moking, to have unstable angina, and to have undergone a
revious PCI. Lesions tended to be longer in U.S.-treated
atients, but were less likely to be ACC/AHA class C
Table 2). U.S. patients also had shorter time to PCI after
ospital admission. Rates of alcohol consumption and
revalence of previous MI were, however, were greater in
atients treated outside the U.S.
Table 2 highlights the differences in the lesion character-
stics as assessed by quantitative coronary analysis in patients
reated inside and outside the U.S. Among the pre-PCI
haracteristics, lesions in patients treated at non-U.S. sites
ere more likely to be complex and diffuse. In contrast, the
re-PCI stenosis was worse in lesions of patients treated in
he U.S., and the pre-PCI reference vessel diameter was
maller in the U.S.-treated lesions. There was no difference
n the post-PCI minimal luminal diameter in the lesions
reated inside and outside the U.S.; however, the postpro-
edure reference vessel diameter remained slightly smaller in
he U.S.-treated patient lesions.
Table 3 shows the rates of ischemic TVR, MI, death, and
VF in patients treated in the U.S. and other countries. It
lso shows the unadjusted and adjusted odds ratios for these
utcomes. Ischemia-driven TVR occurred in a greater
roportion of patients treated in the U.S. than those treated
lsewhere (18% vs. 11%, p  0.01). The rate of TVF was
lso significantly higher among U.S. patients (20%) as
ompared with those patients treated in other countries
12%), although this was predominantly driven by TVR
ates. U.S. patients also had higher rates of death and MI,
lthough these events were rare. After adjustment for the
forementioned potential confounders, U.S. patients re-
ained at significantly increased risk of all events with the
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Geographical Differences in Repeat Revascularization January 3, 2006:34–9xception of death. The increased risk of TVR, TVF, and
I ranged from approximately 40% to 60%.
Table 4 demonstrates the restenosis rates amongst pa-
ients treated in the U.S. and patients treated in other
ountries who underwent protocol-driven follow-up an-
iography. Before and after adjustment for gender, diabetes,
urrent unstable angina, smoking status, previous PCI, any
esion of ACC/AHA type C, length of longest lesion, and
umber of lesions, the likelihood of restenosis was signifi-
able 1. Baseline Clinical Characteristics of Patients Treated at
ites Outside and Inside the U.S. (n  11,484 Patients)
Non-U.S. Site
(n  6,458)
U.S. Site
(n  5,026)
p
Value
ge, yrs 60  10 61  11 0.01
emale 1,210, 19% 1,381, 27% 0.01
aucasian 6,335, 98% 4,580, 91% 0.01
ody mass index, kg/m2 27.4  3.9 29.4  5.3 0.01
urrent smoker 1,505, 23% 1,091, 22% 0.04
lcohol consumption
0 U/week 2,174, 34% 3,128, 62% 0.01
1–14 U/week 3,984, 62% 1,801, 36%
14 U/week 266, 4% 86, 2%
iabetes mellitus 1,209, 19% 1,475, 29% 0.01
ypertension 3,350, 52% 3,661, 73% 0.01
yslipidemia 4,086, 63% 3,360, 67% 0.01
revious MI 2,642, 41% 1,811, 36% 0.01
revious CABG 519, 8% 1,042, 21% 0.01
revious PCI 1,461, 23% 2,090, 42% 0.01
revious carotid
endarterectomy
73, 1% 151, 3% 0.01
istory of CHF 222, 3% 474, 9% 0.01
istory of ACS 3,175, 49% 3,620, 72% 0.01
eripheral vascular disease 302, 5% 377, 8% 0.01
erebrovascular accidents 174, 3% 209, 4% 0.01
ransient ischemic attack 165, 3% 189, 4% 0.01
istory of stable angina 3,077, 48% 2,028, 40% 0.01
istory of unstable
angina
1,650, 26% 1,826, 36% 0.01
urrent stable angina 3,363, 52% 1,362, 27% 0.01
urrent unstable angina 2,515, 39% 3,371, 67% 0.01
tatin use 4,437, 69% 3,954, 79% 0.01
ospital admit to PCI,
days
2.1  3.5 0.8  1.5 0.01
umber of vessels treated 1.19  0.43 1.20  0.44 0.09
umber of lesions 1.39  0.67 1.44  0.69 0.01
xtent of CAD
One-vessel disease 5,339, 83% 4,094, 81% 0.21
Two-vessel disease 1,028, 16% 850, 17%
Three-vessel disease 90, 1% 81, 2%
ndication for PCI
Stable angina 3,820, 59% 1,637, 33% 0.01
Unstable angina 1,911, 30% 2,608, 52%
Unstable angina due to
MI
727, 11% 779, 16%
lycoprotein IIb/IIIa
inhibitor
995, 15% 3,198, 64% 0.01
ontinuous variables reported as mean  1 SD. Categorical variables reported as n,
. 1% missing data.
ACS  acute coronary syndromes; CABG  coronary artery bypass grafting;
AD  coronary artery disease; CHF  congestive heart failure; MI  myocardial
nfarction; PCI  percutaneous coronary intervention.antly higher in the U.S.-treated patients.
%Table 5 shows the number of enrolling sites, number of
atients enrolled, mean days from hospital admission to
CI, and TVR rates by the participating countries. Eigh-
een non-U.S. countries participated in the PRESTO trial,
ith the number of enrolling sites by country ranging from
to 37, and patient enrollment from 48 to 1,022. Mean
ime from hospital admission to PCI ranged from 1.0 to 5.0
ays in non-U.S. sites, with the U.S. having the lowest mean
0.8 days). The rates of TVR at non-U.S. sites ranged widely,
rom 4% in the Czech Republic and Estonia to 16% in
ermany, with the highest rate of 18% occurring in the U.S.
ISCUSSION
his analysis shows that the angiographic restenosis,
schemia-driven TVR, and TVF rates after PCI were all
ignificantly greater for patients treated in the U.S. than
hose patients who were treated in other countries. Previous
tudies have reported differences in countries’ assessments,
reatments, and outcomes for patients with acute MI and
ardiogenic shock (1–4). Limited data are available on the
eographical differences in restenosis rates or rates of
schemia-driven TVR. Our data suggest important baseline,
able 2. Lesion Characteristics From Quantitative Coronary
nalysis (n  3,726 Lesions)
Non-U.S. Site
(n  2,127)
U.S. Site
(n  1,599)
p
Value
re-PCI characteristics
Bend 45° 141, 7% 202, 13% 0.01
Calcified 145, 7% 88, 6% 0.17
Complex 557, 26% 158, 10% 0.01
Diffuse disease 371, 18% 203, 13% 0.01
Discrete 1361, 65% 978, 63% 0.10
Eccentric 881, 42% 591, 38% 0.03
Lesion class
A 395, 19% 319, 20% 0.01
B1 749, 36% 674, 42%
B2 742, 35% 548, 34%
C 205, 10% 55, 3%
Lesion length 11  5 13  8 0.01
Vessel
Right coronary artery 701, 33% 569, 36% 0.01
Left anterior
descending
879, 41% 479, 30%
Circumflex 485, 23% 414, 26%
Left main 21, 1% 21, 1%
Other 37, 2% 112, 7%
Pre-PCI % stenosis 75  14 79  15 0.01
Pre-PCI minimal
luminal diameter
0.9  0.5 0.8  0.5 0.01
Pre-PCI reference vessel
diameter
3.0  0.5 2.8  0.6 0.01
ost-PCI characteristics
Post-PCI % stenosis 14  14 8  11 0.01
Post-PCI minimal
luminal diameter
2.7  0.6 2.7  0.7 0.82
Post-PCI reference
vessel diameter
3.0  0.5 2.9  0.6 0.01
ontinuous variables reported as mean  1 SD. Categorical variables reported as n,
. 1.7% missing data.
PCI  percutaneous coronary intervention.
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January 3, 2006:34–9 Geographical Differences in Repeat Revascularizationngiographic, and procedural differences between countries,
ut these differences between countries did not fully account
or the geographical differences in the rates of restenosis, TVR,
nd TVF. This study is the largest reported to date comparing
he angiographic rates of restenosis and ischemia-driven TVR
n the basis of geographical differences.
There are several potential explanations for the higher
ncidence of both angiographic restenosis and ischemia-
riven TVR rates in the U.S. First, it would be expected that
estenosis would have been predictably higher for U.S.
atients based on the increased frequency of baseline and
ome angiographic variables associated with higher risk for
estenosis and TVR in previous reports (10–13). It is not
urprising, however, that these previously described covari-
tes do not account for all of the increased risk among U.S.
atients noted in our models because most previously
eported models have limited discriminatory power in iden-
ifying restenotic events (14).
Changes in treatment strategy that are not easily ac-
ounted for in the multivariable models also may offer part
f the explanation. Unstable angina is known to be associ-
ted with higher rates of revascularization and can partly
xplain the higher incidence of both restenosis and
schemia-driven TVR. Approximately two-thirds of patients
reated in the U.S., and fewer (39%) in other countries, had
his diagnosis. Perhaps more importantly, there is a distinct
ifference in the invasive approach to patients with acute
oronary syndrome in the U.S. as compared with other
ountries. Very early revascularization, as practiced in the
.S., has been shown to increase the rates of repeat
able 3. Clinical Outcomes
Non-U.S. Site
(n  6,458)
U.S. Site
(n  5,026) p Value
VR 680, 11% 929, 18% 0.01
Odds ratio 1.00 1.93 0.01
95% CI — (1.73–2.14)
Adjusted odds ratio* 1.00 1.48 0.01
95% CI — (1.32–1.66)
I 65, 1% 93, 2% 0.01
Odds ratio 1.00 1.85 0.01
95% CI — (1.35–2.55)
Adjusted odds ratio* 1.00 1.57 0.01
95% CI — (1.11–2.21)
eath 59, 0.9% 73, 1.5% 0.01
Odds ratio 1.00 1.60 0.01
95% CI — (1.13–2.26)
Adjusted odds ratio* 1.00 1.13 0.52
95% CI — (0.78–1.64)
VF (TVR, MI, or death) 754, 12% 1,002, 20% 0.01
Odds ratio 1.00 1.88 0.01
95% CI — (1.70–2.09)
Adjusted odds ratio* 1.00 1.43 0.01
95% CI — (1.28–1.60)
Adjusted for gender, diabetes, current unstable angina, smoking status, previous
ercutaneous coronary intervention, any lesion of American College of Cardiology/
merican Heart Association type C, and length of longest lesion.
CI  confidence interval; MI  myocardial infarction; TVF  target vessel
ailure; TVR  target vessel revascularization.evascularization (5). In a retrospective analysis from the
AURSUIT trial, it was demonstrated that rates of repeat
evascularization in patients with unstable angina were
otably higher for PCI within 24 h (19%) than for PCI at
4 to 72 h (17%), 3 to 7 days (13%), and 8 to 30 days (8%)
5). In our study, the mean time from hospital admission to
CI at U.S. sites was 0.8 days as compared with 2.1 days at
he non-U.S. sites. These rates match the practice patterns
f different countries in the present study, with an ischemic
VR rate of 18% in the U.S., where aggressive intervention
s practiced, and a rate of 11% outside the U.S., including
he United Kingdom, Western Europe, and South Africa,
here greater delays for invasive management occur after
nitial medical stabilization. However, contrary to the PUR-
UIT study, our analysis did not find any significant effect
f time to treatment on TVR in patients treated with a
iagnosis of acute coronary syndrome (data not shown).
Higher amounts of alcohol consumption in patients treated
utside the U.S. might have conferred some protection from
epeat revascularization. Alcohol consumption in small-to-
oderate amounts has been shown to reduce mortality and
I (15). Some animal data support a beneficial role of
lcohol in terms of reducing the smooth muscle hyperplasia
n response to balloon injury of the coronary arteries (16,17),
nd it is conceivable that this mechanism might be partly
esponsible for lower events in the patients treated outside the
.S. Similarly, a higher prevalence of previous MI could be a
actor associated with lower subsequent revascularization, as
bserved in patients treated outside the U.S. (10,18).
A major problem in the analysis of restenosis and TVR
ates is the modest-to-poor predictive ability of the known
emographic and angiographic variables. We previously
emonstrated poor discriminatory ability of models derived
rom the PRESTO trial in predicting angiographic reste-
osis and ischemic TVR (9,14). It implies, therefore, that
able 4. Restenosis Outcomes From Quantitative Coronary
nalysis at Nine-Month Follow-Up
Non-U.S. Site
(n  1,277)
U.S. Site
(n  819) p Value
ny stenosis 50% 417, 33% 412, 50% 0.01
Odds ratio 1.00 2.09 0.01
95% CI — (1.74–2.50)
Adjusted odds ratio* 1.00 1.69 0.01
95% CI — (1.38–2.07)
ny loss of gain 50% 561, 44% 484, 59% 0.01
Odds ratio 1.00 1.84 0.01
95% CI — (1.54–2.20)
Adjusted odds ratio* 1.00 1.54 0.01
95% CI — (1.27–1.88)
ny stenosis or loss of
gain 50%
610, 48% 529, 65% 0.01
Odds ratio 1.00 2.00 0.01
95% CI — (1.66–2.39)
Adjusted odds ratio* 1.00 1.71 0.01
95% CI — (1.39–2.09)
Adjusted for gender, diabetes, current unstable angina, smoking status, prior
ercutaneous coronary intervention, any lesion of American College of Cardiology/
merican Heart Association type C, length of longest lesion, and number of lesions.
CI  confidence interval.
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Geographical Differences in Repeat Revascularization January 3, 2006:34–9here are some important, unmeasured determinants of
estenosis and TVR that are not considered in the present
tudy. Knowledge and addition of these variables is para-
ount in determining the reasons for geographic disparity
n the rates of restenosis and TVR (19,20).
tudy limitations. The need for TVR was based on trial
ecommendations and hence less likely reflected the discre-
ion of the attending physician, or differences in the practice
atterns of different investigators and hospitals. However,
hest pain was included as one of the reasons for TVR,
hich could have led to higher revascularization procedures
n the U.S. In addition, the attitudes of patients, physicians,
nd society toward treatment for patients also may be
mportant factors. The aggressiveness of medical care and
ccess to health care are important confounders that were
ifficult to consider properly in the present study. The
ngiographic study was prespecified in the trial; however, we
annot totally exclude withdrawal bias due to incomplete
ngiographic follow-up.
onclusions. In conclusion, geographical differences in
ngiographic restenosis and ischemia-driven TVR were
bserved. Patients treated in the U.S. have a higher preva-
ence of many baseline demographic and angiographic
eatures associated with higher angiographic restenosis and
eed for repeat revascularization, but these differences
etween countries did not account completely for the
eographical differences in restenosis and TVR.
eprint requests and correspondence: Dr. David R. Holmes, Jr.,
ivision of Cardiovascular Diseases, Department of Internal
edicine, Mayo Clinic, 200 2nd Street SW, Rochester, Minne-
able 5. TVR Rates by Country
No. of Sites No. of Patients
H
t
zech Republic 3 350
stonia 1 67
ustralia 5 131
celand 1 48
pain 16 946
nited Kingdom 13 391
orway 4 91
outh Africa 3 61
taly 26 536
oland 3 192
elgium 11 330
inland 5 211
he Netherlands 10 198
anada 27 802
weden 4 176
enmark 3 114
rance 37 1,022
ermany 36 792
.S. 224 5,026
Compared with U.S. †Adjusted for gender, diabetes, current unstable angina, smok
ssociation type C, and length of longest lesion.
CI  confidence interval; PCI  percutaneous coronary intervention; TVR  taota 55905. E-mail: holmes.david@mayo.edu.EFERENCES
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